Actively Recruiting

Phase 3
Age: 18Years +
All Genders
NCT07381803

The Impact of Fexofenadine Hydrochloride on the Prognosis of Patients Post-Acute Myocardial Infarction

Led by Second Affiliated Hospital, School of Medicine, Zhejiang University · Updated on 2026-02-02

2804

Participants Needed

1

Research Sites

122 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The goal of this study is o evaluate the prognostic effect of fexofenadine hydrochloride in patients with myocardial infarction

CONDITIONS

Official Title

The Impact of Fexofenadine Hydrochloride on the Prognosis of Patients Post-Acute Myocardial Infarction

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 63 18 years old
  • Able to verbally confirm understanding of the trial risks, benefits, and treatment options of fexofenadine hydrochloride therapy and provide written informed consent
  • Acute ST-segment elevation myocardial infarction (STEMI) within 7 days, with typical clinical symptoms, elevated serum cardiac troponin, and new ST-segment elevation in 2 adjacent leads
  • Echocardiography showing segmental wall motion abnormalities
Not Eligible

You will not qualify if you...

  • Need for long-term use of fexofenadine hydrochloride or other H1 receptor inhibitors
  • Previous coronary artery bypass grafting (CABG) surgery
  • History of severe renal failure with eGFR < 30 ml/min
  • History of severe liver dysfunction
  • History of severe infection, hepatobiliary obstruction, or malignant tumor
  • Expected life expectancy less than 2 years due to non-cardiac diseases
  • Currently receiving immunosuppressive therapy
  • Pregnant, potentially pregnant, or lactating women
  • Contraindication to the study drug or examinations
  • Failure to provide written informed consent
  • Presence of mechanical complications, refractory cardiogenic shock, acute left heart failure, pulmonary edema, or uncontrolled malignant arrhythmias at enrollment

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

The Second Affiliated Hospital of Zhejiang University, School of Medicine

Hangzhou, Zhejiang, China, 310000

Actively Recruiting

Loading map...

Research Team

C

Cheng Ni

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

TRIPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here